Nyvepria (Pegfilgrastim)

Pegfilgrastim, the active ingredient in Nyvepria, is a long‑acting colony‑stimulating factor presented as a sterile powder for subcutaneous injection use. It reduces the duration of neutropenia in patients receiving myelosuppressive chemotherapy. GNH USA supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Nyvepria as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Nyvepria is a pegylated filgrastim indicated for neutrophil recovery in chemotherapy‑treated patients. - Breast cancer: helps restore neutrophil counts after myelosuppressive regimens. - Lung cancer: supports neutrophil recovery following cytotoxic therapy. - Non‑Hodgkin lymphoma: reduces the duration of chemotherapy‑induced neutropenia. - Small‑cell lung cancer: shortens neutropenia episodes during treatment. - Acute myeloid leukemia: assists in neutrophil recovery after intensive chemotherapy. - Peripheral blood stem‑cell mobilization: facilitates stem‑cell collection when used with chemotherapy.

Adverse reactions to pegfilgrastim are reported across a range of severity.

Common Side Effects: - Bone pain, especially in the long bones. - Musculoskeletal discomfort. - Injection‑site erythema or pruritus. - Fatigue or mild headache. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Splenic rupture or enlargement. - Acute respiratory distress syndrome. - Severe allergic reactions including anaphylaxis. - Vasculitis or capillary leak syndrome. - Unexplained leukocytosis. - Thromboembolic events.

When using Nyvepria, clinicians should consider patient‑specific factors and follow recommended monitoring.

- Renal impairment: adjust monitoring of blood counts and fluid status. - Hepatic dysfunction: observe for prolonged neutropenia recovery. - Prior splenic disorders: assess risk of splenic enlargement. - Concomitant chemotherapy: coordinate timing to avoid overlapping toxicities. - Pregnancy and lactation: evaluate risk‑benefit ratio before use. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Pegfilgrastim may interact with other agents that affect bone‑marrow function or immune response.

Major Interactions (Avoid): - Myelosuppressive chemotherapy given within 24 hours of pegfilgrastim injection. - High‑dose corticosteroids administered concurrently.

Moderate Interactions (Monitor Closely): - Anticoagulants, due to potential increased bleeding risk from thrombocytopenia. - Immunosuppressive biologics, which may blunt neutrophil response. - Radiotherapy involving large bone‑marrow fields. - Drugs that cause hypersensitivity reactions, requiring close observation. - Live vaccines, as immune modulation may affect vaccine efficacy.